In the rapidly evolving landscape of digital health, the intersection of patient engagement and regulatory compliance has always been a point of friction. Faisal Zain has spent his career navigating these complexities, specifically focusing on how medical innovations are communicated to the public in a way that is both impactful and legally sound. As pharmaceutical brands shift their focus toward social-first environments, the tools they use to maintain transparency while driving action are becoming more sophisticated. Today, we explore how platforms like Snapchat are redefining the traditional “one-click” advertisement and what this means for the future of patient-caregiver dialogues.
The following discussion examines the transition from static advertisements to multi-layered engagement models within social media. We delve into the strategic advantages of providing multiple safety and information destinations within a single ad unit, the shifting demographics of mobile-first platforms, and the ongoing tension between creative freedom and the stringent requirements of Medical Legal Regulatory (MLR) teams.
Snapchat has recently moved beyond the single-link limitation by offering a multi-CTA model that allows for three disclaimer links beneath a primary call to action. From a strategic standpoint, how does this change the way a pharmaceutical brand can architect its patient journey within a single mobile ad?
This shift is a fundamental departure from the “all-or-nothing” approach we have seen for years in digital pharma marketing. By allowing up to three additional disclaimer links alongside the primary attachment, brands can finally mirror the complexity of a real-world medical conversation within a high-speed mobile environment. Instead of forcing a user to leave the app and hunt for information, a marketer can now provide direct paths to the Prescribing Information, the Medication Guide, and the safety summary simultaneously. It allows us to build a “trust architecture” right at the point of first contact, which is essential when you consider that 95% of Snapchat users are already expressing an active interest in health and wellness conversations. We are no longer just dropping a link; we are providing a curated resource hub that fits in the palm of a hand.
There is a lingering perception that Snapchat is exclusively for a younger audience, yet the data suggests a significant demographic shift is underway. How should medical marketers view the platform’s current user base when deciding where to allocate their increasingly tight budgets?
The narrative that this is just an app for teenagers is outdated and frankly ignores the massive opportunity for reaching the “sandwich generation” of caregivers. Currently, half of the Snapchatters in the U.S. are over the age of 25, and the 35-plus demographic is actually the platform’s fastest-growing segment. These are the people making high-stakes healthcare decisions for both their children and their aging parents, making them a prime audience for sophisticated medical messaging. When you have a global reach of 971 million monthly active users, you aren’t just looking for volume; you are looking for those millennial patients who prefer vertical, episodic content over traditional TV spots. Ignoring this demographic shift means missing out on the very people who are most likely to advocate for a specific treatment path during a doctor’s visit.
The Eli Lilly campaign featuring Caitlin Clark has been cited as a successful example of proactive health dialogue. What specific elements of that campaign demonstrate the potential for drugmakers to move from reactive safety disclosures to proactive health advocacy?
The “Start How You Can” campaign was a masterclass in using cultural momentum to normalize a health conversation that might otherwise feel clinical or intimidating. By partnering with a high-profile athlete like Caitlin Clark, Lilly was able to pivot the dialogue from a reactive discussion about illness to a proactive one about lifestyle and health management. They utilized the conversational nature of the app to meet users where they were already talking about sports and wellness, rather than trying to interrupt their flow with a generic commercial. This approach works because it feels native to the platform—it’s shareable, it’s conversational, and it leverages the unique social-first format that Snapchat has perfected. It proves that if the creative is designed for the platform’s specific engagement style, pharma can actually participate in “cultural moments” without losing its professional integrity.
Compliance remains a major hurdle, and many MLR teams are hesitant about safety information living behind links rather than being integrated into the creative. How does this new multi-CTA format address those “workaround” challenges that have plagued short-form video content for years?
For a long time, we were trying to shove ten pounds of safety data into a five-pound bag, resulting in tiny, unreadable text or awkward “swipe up” instructions that users ignored. This multi-CTA model is a strategic solution because it keeps critical safety and disclosure links visible inside the ad unit even as the brand optimizes for the primary goal, like a doctor-discussion guide. It provides a dedicated space for those mandatory links, which helps satisfy the proposed FDA regulations that seek more clarity in DTC advertising. By having these links “docked” at the bottom of the screen, we create a persistent safety presence that doesn’t detract from the visual storytelling of the ad itself. It’s about creating a “safety-first” environment that doesn’t sacrifice the aesthetic quality of the campaign, which is the only way to get MLR teams to truly buy into social-first media.
When looking at the broader social media landscape, Snapchat still trails behind giants like YouTube and Facebook in terms of being a primary destination for health searches. Given that only 14% of users currently go to Snapchat for health info, what is the argument for including it as a secondary or ancillary channel?
While it’s true that YouTube remains the giant at 66% and Facebook sits at 50% for health information seeking, focusing only on search intent misses the power of peer-to-peer influence and discovery. Snapchat shouldn’t be the place where you try to capture someone searching for a specific diagnosis; it’s where you reinforce the brand through a “social takeover” or a conversational story. I view it as a high-impact ancillary channel that hits the audience at a different point in the marketing funnel—moving them from awareness to a personal, shareable dialogue. You use the 42% reach of Instagram for the broad discovery, but you use Snapchat for the deeper, more personal relationship-building that occurs in a private messaging environment. It’s about the quality of the engagement and the ability to spark a one-on-one conversation that a public-facing platform like YouTube doesn’t always facilitate.
The lack of granular reporting for individual disclaimer links is a notable limitation in the current Ads Manager. How should advertisers measure the success of their campaigns if they can’t see exactly which safety link a user clicked?
Currently, we have to look at the “halo effect” and the primary CTA performance, which I admit is a challenge for those of us who live by granular data. Snapchat has clarified that they provide reporting for the main attachment but haven’t yet separated the secondary links, so we have to measure success through overall site traffic spikes and engagement rates with the primary content. We look for qualitative signals—are people sharing the content, and are we seeing a lift in brand sentiment or disease state awareness? As the platform evolves its measurement capabilities, we expect to see more specific pathing data, but for now, the metric is the strength of the dialogue we are creating. If a user is spending time with a Sponsored Snap or a Story Ad, the engagement itself is a proxy for the value they are finding in that health education.
What is your forecast for the role of social-first platforms in pharmaceutical marketing over the next two years?
I anticipate we are entering an era of “radical transparency” where the friction between clinical data and social engagement finally disappears. Over the next two years, we will see more platforms adopt these multi-destination models as they realize that pharma dollars will only flow where compliance is a built-in feature, not a manual workaround. We will move away from repurposing 30-second TV spots and instead see brands launching episodic, vertical series designed specifically for patient-to-caregiver sharing. By 2028, the most successful drug launches won’t just be measured by prescriptions, but by how many “conversational shares” they generated in private messaging environments. The brands that win will be the ones that stop treating social media as a broadcast tower and start treating it as a consultation room where information is accessible, multi-layered, and deeply personal.
